Koninklijke Philips N.V. (PHG)
| Previous close | 19.98 |
| Open | 20.03 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1300 |
| Day's range | 19.95 - 20.14 |
| 52-week range | 17.75 - 24.27 |
| Volume | |
| Avg. volume | 1,027,769 |
| Market cap | 18.246B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.51 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 12 May 2022 |
| 1y target est | 20.70 |
ZacksPhilips (PHG) Agrees to a Consent Decree With DOJ and FDA
Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.
GlobeNewswirePhilips Respironics reaches agreement with US government on a consent decree creating a clear path forward
April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA and Philips Respironics have now reached final agreement on the consent decree with the DOJ and FDA. As previously stated: The consent decree primarily focuses on Philips Respironics’ business operations in the US.It provides clarity and a roadmap to demonstrate compliance with regulatory requirements and to restore
- Reuters
US federal court orders Philips to restrict production of sleep apnea devices
(Reuters) -A U.S. federal court issued a decree to restrict the production and sale of Philips' new sleep apnea machines at several facilities in the country, the Food and Drug Administration said on Tuesday. The U.S. District Court for the Western District of Pennsylvania has entered into what is known as a consent decree against the company's subsidiary Philips Respironics to curb the sale and production until certain requirements are met. In January, the Dutch health technology company had said that it will not sell new devices to treat sleep apnea in the United States in the coming years as it works to comply with a settlement with the FDA.
